Isn't OBJ's transdermal drug delivery technology being used by Vaxxas?
http://www.vaxxas.com/news/vaxxas-raises-a$25-million-(us$20-million)-in-series-b-venture-financing/
From the above article:
In order to capitalize on the numerous opportunities to commercialize its proprietary Nanopatch™ platform, Vaxxas is pursuing strategic plans to both license its technology to global pharmaceutical companies as well as advance vaccine candidates on its own. Vaxxas has a collaboration with Merck & Co. Inc. to evaluate, develop and commercialize Vaxxas' Nanopatch™ vaccine delivery platform for undisclosed vaccine candidates developed by Merck.
I imagine that OBJ would be very much bound by nondisclosure agreements, plus they are a supplier of technology to Vaxxas, who has a collaboration with Merck. There is no way OBJ will let us know what is happening until there are developments and announcements about further use of the vaccine patches by these companies first.
Hopefully one day we will be knocked off our seats with new info.
- Forums
- ASX - By Stock
- WFL
- Ann: SK-II Success and Forward Planning
Ann: SK-II Success and Forward Planning, page-151
-
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
KAI
Pilbara Minerals buys land off Kairos part of its York gold project for $20M – and a 2% royalty on any PLS gold sales
AVH
Avita boosts skin restoration product portfolio with 'dermal matrix' – a kind of next-level gauze made of fake skin
Add WFL (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.478M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
WFL (ASX) Chart |
Day chart unavailable